Biogen Idec is collaborating with Orphan Biovitrum on a clinical trial to evaluate the safety and efficacy of a recombinant Factor IX Fc fusion protein in preventing bleeding in hemophilia B patients. Biogen Idec also received FDA approval to market Ampyra, a multiple sclerosis drug it owns with Acorda Therapeutics.

Related Summaries